Document:

EX-10.19

 Exhibit 10.19 
  

 
 March 18, 2012 
 Arlene
Morris 
 [Address] 
 Dear Arlene: 

I am writing to confirm our recent conversations. I am pleased to offer you employment as Chief Executive Officer (“CEO”) of Syndax Pharmaceuticals,
Inc. (the “Company”). Effective as of March 19, 2012, you will be working out of the Company’s offices in Boston and your office in South Carolina. 

1. Position. As CEO, you will be the senior most officer of the Company and have such duties and responsibilities typically associated with such senior
officer, and you shall report to the Company’s Board of Directors (“Board”). During your employment, you shall devote substantially all of your business efforts and time to the Company; provided, however, that you may continue to
serve as a member of corporate boards of directors on which you serve on the date of this Agreement so long as such activities do not materially interfere with the discharge of your duties as CEO. 

2. Compensation and Benefits. Your compensation includes a Base Salary at an annualized rate of $400,000. You also will be eligible for those
employment benefits that the Company may offer its employees generally. Currently these benefits include: health insurance, vacation days, and participation in the Company’s 401(k) plan. These benefits are governed by the terms and conditions
contained in the applicable plans or policies, and they are subject to change or discontinuation at any time, at the discretion of the Company. 
 3.
Annual Bonus. You will be eligible to receive an annual Target Bonus of up to forty percent (40%) of your base annual salary, based on the successful satisfaction of objectives set by the Company’s Board. You and the Board will, in
good faith, agree upon written performance goals with respect to such Target Bonus no later than February 28th of each year prior to the completion of Company’s initial public offering (“IPO”). After the IPO, you will consult
with the Board prior to the establishment of written performance goals in accordance with the Company’s then existing policies and procedures. The Target Bonus for each year, if any, will be paid to you no later than March 15th of the
following calendar year; provided that, except as otherwise set out herein, you will not be eligible to earn any Target Bonus unless you are employed by the Company on the date when such bonus is paid. 

4. Initial Grant of Stock Options. In connection with the commencement of your employment, the Company will grant to you at its next regularly
scheduled Board meeting an option to purchase 967,278 shares of the Company’s common stock (equal to approximately 1% of the Company’s issued and outstanding capital stock on a fully-diluted basis as of the date of this offer letter) at an
exercise price per share equal to the fair market value per share of the Company’s common stock on the date of grant (as determined by the Board on the date of grant). 

  
 Syndax Pharmaceuticals, Inc., 460 Totten
Pond Road, Suite 650, Waltham, MA 02451 Telephone: 781.419.1400 Fax: 781.419.1420 

			
	Arlene Morris	  	  -
 2
 -

  

 The option shares issuable pursuant to this initial grant shall be immediately exercisable, subject to
vesting and other terms and conditions set forth in the grant agreement, including that 25% of the shares issuable shall vest on the one year anniversary of the your employment commencement date (the “Vesting Commencement Date”) and 1/36th
of the remaining shares shall vest at the end of each month following the one year anniversary of such Vesting Commencement Date. In the event you exercise any options prior to the time such options have vested, any unvested shares shall be subject
to a right of repurchase by the company at cost in the event your employment terminates for any reason. In connection with a Change of Control (as defined below) of the Company, all such options shall accelerate and become fully vested. 

5. Additional Grant of Stock Options. In connection with an initial public offering (“IPO”) of the Company’s common stock, subject to
approval by the Company’s Board, immediately prior to the pricing of an IPO, the Company will grant to you an option to purchase up to such number of shares of common stock as would be necessary to permit you to have a post-IPO ownership
interest in the Company of 1% on a fully diluted basis. Each share of common stock available for purchase under this additional stock option grant shall have an exercise price per share equal to the fair market value per share of the Company’s
common stock on the date of the grant, and shall vest in accordance with the Company’s standard vesting schedule beginning on the Vesting Commencement Date. 

6. Strategic Transaction Carve-out. In connection with a Change of Control of the Company, pursuant to the carve-out plan adopted by the Board then in
effect, you shall receive prior to calculation of any payment or distribution of proceeds to stockholders a cash payment equal to the 2% of the net proceeds received in the Change of Control that are payable to stockholders after payment of any
transaction-related expenses. Such payment shall be made upon the closing of the Change of Control and shall be subject to any escrow or contingent payment holdbacks applicable to the Company’s stockholders, and shall be subject to any vesting
requirements set forth in the carve out plan on the terms attached hereto as Exhibit A. Such carve-out plan shall terminate immediately upon the closing of the Company’s IPO. 

7. Promissory Note. Prior to filing a registration statement with the Securities Exchange Commission (the “SEC”), the Company will loan you
the amount necessary to exercise any or all of your outstanding options in the event that you choose to exercise such options prior to an IPO (the “Note”). The parties acknowledge and agree that, to the extent you exercise unvested options
with a Note, it is your intention to file an election under Section 83(b) of the Internal Revenue Code for purposes of preserving capital gains treatment on the underlying shares. Unvested shares, once purchased, shall be subject to the same
restrictions and obligations as are set out in your option agreements including a right of repurchase of any unvested shares at cost in the event your employment with the Company terminates for any reason. The Note will include such customary terms
as are required for an employment-related “deemed demand” loan under the Internal Revenue Code, which shall include your unconditional promise to repay the note within the five (5) years from the date of the making, interest at a
market interest rate to be determined (which shall be equal to the Applicable Federal Rate on the date of making), pledge of your stock as collateral, and requirement to prepay the note upon the earliest to occur of sale of all or any portion of
such collateral (such prepayment applicable only with respect to the number of collateralized shares sold), your termination for Cause or resignation without Good Reason, or the filing of the Company’s first registration statement with the SEC.

 8. Board Seat. You shall continue to be a member of the Board, but you shall not receive any additional compensation for your role as a member of
the Board. In addition, your Board seat shall constitute the seat reserved for the CEO of the Company and you will no longer be considered an independent member of the Board. 

  
 Syndax Pharmaceuticals, Inc., 460 Totten
Pond Road, Suite 650, Waltham, MA 02451 Telephone: 781.419.1400 Fax: 781.419.1420 

			
	Arlene Morris	  	  -
 3
 -

  

 9. Duration. Although we expect a long and successful relationship, your employment will be at will,
meaning that you or the Company can terminate it at any time, with or without Cause or notice. If the Company terminates your employment without Cause (which includes as a result of a Change of Control), or if you resign for Good Reason, and
provided that you satisfy the Conditions, you shall receive the following severance benefits on the 60th day following your termination date: 
 (a) A lump
sum payment equal to the sum of twelve (12) months of your then-current Base Salary (less applicable payroll withholding); 
 (b) Acceleration of
vesting with respect to your outstanding equity awards as to the number of shares that would have otherwise vested during the twelve (12) month period following your termination date; and 

(c) If you elect, continuation coverage under its health plans (“COBRA” coverage) for you (and, if applicable, your dependents enrolled as
participants in such health plans as of the date of termination) the Company shall pay the full premium for such coverage for the twelve-month period following your termination date. In the event you become covered by another employer’s plan
that offers health plan benefits, such COBRA coverage shall immediately cease. To the extent such coverage cannot be provided under the Company’s group health plan without jeopardizing the tax status of such plan or for underwriting reasons,
the Company shall pay you an amount equal to the full premiums foir a twelve-month period in a single lump sum. 
 As used in this paragraph: 

“Cause” means (a) a substantial and repeated failure to perform your job duties, unless any such failure is corrected within thirty
(30) days if such cure will fully repair any failure, following written notice by the Board or its delegate that specifically identifies the manner in which you have failed to substantially performed your duties or; (b) breach of your
fiduciary duties to the Company; (c) misappropriation Company assets or fraud that is injurious to the Company; (d) your willful violation of a material Company policy; or (e) the conviction of a felony or other crime involving moral
turpitude. No act, or failure to act, by you shall be “willful” unless committed without good faith and without a reasonable belief that the act or omission was in the best interest of the Company. 

“Conditions” means (a) you have returned all Company property in your possession within 10 days following your termination, and (b) you
have executed a full and complete general release of all claims that you may have against the Company or persons affiliated with the Company in a form acceptable to the Company (which shall include, among other terms, a mutual non-disparagement
clause) and such release has become effective no later than the 30th day after your termination. 
 “Good Reason” means, without
your express written consent, the occurrence of any of the following events: (a) a material diminution of your authority, duties or responsibilities with the Company taken as a whole; (a) a greater than 10% reduction by the Company in your
Base Salary as in effect immediately prior to such reduction unless such reduction occurs in connection with an across-the-board reduction in base salaries of other similarly situated employees; (c) the requirement to establish residence in a
location more than 50 miles from your current residence; and (d) the failure of the Company to obtain the assumption of this employment agreement by 

  
 Syndax Pharmaceuticals, Inc., 460 Totten
Pond Road, Suite 650, Waltham, MA 02451 Telephone: 781.419.1400 Fax: 781.419.1420 

			
	Arlene Morris	  	  -
 4
 -

  

 
any successor company. You must give the Company written notice describing the Good Reason event in reasonable detail within ninety (90) days of your actual knowledge of the occurrence of
the Good Reason event. The Company shall have thirty (30) days after its receipt of written notice to reasonably cure the event or condition cited in the written notice so that Good Reason will have not formally occurred as a result of the
event in question until such cure period has expired. A termination of employment due to Good Reason shall occur no later than thirty (30) days after the expiration of such cure period or on notification by the Company that it does not intend
to cure, whichever is earlier. For purposes of notice under this paragraph, if yours authority, responsibility or duties are materially diminished incrementally over a period of time (not to exceed twelve months), the “event” shall be
deemed to occur when such reduction, in the aggregate, becomes material. 
 “Change of Control” means (a) the Company
transfers all or substantially all of its assets, unless, immediately after consummation of such transaction, the shareholders of the Company immediately prior to the transaction hold, directly or indirectly, more than 50% of the voting stock of
the; or (b) any merger, reorganization, consolidation or similar transaction, unless, immediately after consummation of such transaction, the shareholders of the Company immediately prior to the transaction hold, directly or indirectly, more
than 50% of the voting stock of the transferee. For clarity, a Change of Control shall not include any sale of stock to the public or otherwise undertaken primarily for financing purposes. 

10. Reimbursement of Expenses. The Company will reimburse you for your necessary and reasonable business expenses incurred in connection with your
duties in accordance with the Company’s generally applicable policies. You and the Company acknowledge that you will be required to spend a certain amount of time each month at the Company’s Boston headquarters. Accordingly, the Company
will reimburse, or pay for, all reasonable expenses incurred by you in connection with commuting between the Company’s Boston and South Carolina offices, including your actual and reasonable living expenses incurred in the Boston area and your
actual and reasonable commuting expenses incurred between Boston and your current principal residence in South Carolina, including, if applicable, hotel accommodations, a corporate apartment lease, furniture rental, airfare for commercial air travel
in business or a lower class cabin, and ground transportation up to a maximum of $10,000 per month. In addition, the Company agrees to provide you with a one-time reimbursement of your reasonable attorneys’ fees incurred in connection with the
negotiation and execution of this Agreement, not to exceed $10,000. 
 For the avoidance of doubt, to the extent that any reimbursements payable by the
Company to you under this Agreement or otherwise are subject to the provisions of Section 409A of the Internal Revenue Code, any such reimbursements will be paid no later than December 31st of the year following the year in which the
expense was incurred, the amount of expenses reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and the right to reimbursement will not be subject to liquidation or exchange for another benefit. 

11. Section 409A. For purposes of Section 409A of the Internal Revenue Code, each payment that is paid pursuant to Section 9 is hereby
designated as a separate payment. The parties intend that all payments made or to be made under this Agreement comply with, or are exempt from, the requirements of Section 409A so that none of the payments or benefits will be subject to the
adverse tax penalties imposed under Section 409A, and any ambiguities herein will be interpreted to so comply or be so exempt. Specifically, any severance payments made in connection with your separation from service under this Agreement and
paid on or before the 15th day of the 3rd month following the end of your first tax year in which your separation from 

  
 Syndax Pharmaceuticals, Inc., 460 Totten
Pond Road, Suite 650, Waltham, MA 02451 Telephone: 781.419.1400 Fax: 781.419.1420 

			
	Arlene Morris	  	  -
 5
 -

  

 
service occurs, or, if later, the 15th day of the 3rd month following the end of the Company’s first tax year in which your separation from service occurs, is intended to be exempt pursuant
to Treasury Regulation Section 1.409A-1(b)(4) and any additional severance provided in connection with your separation from service under this Agreement is intended to be exempt from Code Section 409A pursuant to Treasury Regulation
Section 1.409A-1(b)(9)(iii) (to the extent it is exempt pursuant to such section it will in any event be paid no later than the last day of your 2nd taxable year following the taxable year in which your separation from service has occurred).
Notwithstanding the foregoing, if any of the payments provided in connection with your separation from service does not qualify for any reason to be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(4), Treasury
Regulation Section 1.409A-1(b)(9)(iii), or any other applicable exemption and you are, at the time of your separation from service , a “specified employee,” as defined in Treasury Regulation Section 1.409A-1(i) (i.e., you are a
“key employee” of a publicly traded company), each such payment will not be made until the first regularly scheduled payroll date of the 7th month after your separation from service and, on such date (or, if earlier, the date of your
death), you will receive all payments that would have been paid during such period in a single lump sum. 
 12. Golden Parachute Excise Tax. In the
event that the Company undergoes a “change of ownership” within the meaning of Section 280G of the Internal Revenue Code, the Company shall make good faith efforts to obtain the stockholder approval required to satisfy the exemption
set out in Section 280G(b)(5) of the Code and prior to such stockholder approval, you will waive your entitlement to receive any amount that would be subject to the excise tax imposed by Section 4999 of the Code (the “Excise
Tax”) if such approval is not obtained. If the Company decides not to seek such stockholder approval in good faith because of a determination that such approval is unlikely to be obtained and a payment or benefit received by you pursuant to
this Agreement (a “Payment”) would constitute an “excess parachute payment” within the meaning of Section 280G subject to the Excise Tax, such Payment shall be equal to a reduced amount. Such reduced amount shall be
calculated as either (i) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (ii) the largest portion, up to and including the total, of the Payment, whichever amount, after
taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater amount of the
Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the reduced amount, the
reduction shall occur in the following order: reduction of cash payments; cancellation of accelerated vesting of stock awards, if applicable; reduction of employee benefits. The accounting firm engaged by the Company (or its successor) for general
tax purposes shall perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The accounting firm engaged to make the determinations hereunder
shall provide its calculations, together with detailed supporting documentation, to you and the Company within 15 calendar days after the date on which your right to a Payment is triggered. Any good faith determinations of the accounting firm made
hereunder shall be final, binding and conclusive upon you and the Company. 
 13. Choice of Law and Severability. This Agreement will be interpreted
in accordance with the laws of the State of Delaware without giving effect to provisions governing the choice of law. If either party hereto brings any action to enforce his or its rights hereunder, the prevailing party in any such action will be
entitled to recover her or its reasonable attorneys’ fees and costs incurred in connection with such action. 
 When you report for work, you will need
to provide for our review documents necessary to establish employment eligibility verification as required by the Immigration and Naturalization Service. You will also be required, as a condition of employment, to execute a Confidentiality and
Proprietary Inventions Agreement in the form approved by the Board. 

  
 Syndax Pharmaceuticals, Inc., 460 Totten
Pond Road, Suite 650, Waltham, MA 02451 Telephone: 781.419.1400 Fax: 781.419.1420 

			
	Arlene Morris	  	  -
 6
 -

  

 Please acknowledge this letter and return it to me. We look forward to your joining the Company on
March 19, 2012. If you have any further questions or require additional information, please feel free to contact me. 
  

			
	Sincerely,
	
	SYNDAX PHARMACEUTICALS, INC.
	
	By: /s/ Dennis Podlesak
	
	Dennis Podlesak
	Chairman of the Board
	Syndax Pharmaceuticals, Inc.
		
	Acknowledged:	 	 /s/ Arlene M. Morris

		 	Arlene Morris
	
	Date: 3/20/2012

  
 Syndax Pharmaceuticals, Inc., 460 Totten
Pond Road, Suite 650, Waltham, MA 02451 Telephone: 781.419.1400 Fax: 781.419.1420 

			
	Arlene Morris	  	  -
 7
 -

  

 Exhibit A 

Syndax Pharmaceuticals, Inc. 
 2012 Strategic
Transaction Bonus Plan 
 Total Pool: 

4.5% of cash proceeds actually paid to investors, net of transaction costs and escrow, in a Change of Control, including a strategic partnering
transaction (as defined in definitive agreement). (e.g. Total proceeds to be paid in connection with transaction = $100m; Investors $95.5m; Plan participants, up to $4.5m). 

Stockholder Approval: 
 Subject to
approval of the stockholders of the Company pursuant to the current governance documents and agreements to which the stockholders are party. 

Apportionment: 
  

					
	 Arlene Morris
	  	 	2.0	% 
	 Joanna Horobin
	  	 	1.5	% 
	 Discretionary
	  	 	1.0	% 

 Board Discretion: 

Discretionary apportionment subject to the discretion of the Board with respect to all terms and conditions, including caps, applicability to
upfront proceeds and/or contingent payments and vesting. 
 Plan Termination: 

On the earlier of Company’s initial public offering or the termination of employment of a participant for “Cause” by the
Company, or not for “Good Reason” by such participant. 
 Specific Grants: 

 

			
	Arlene Morris
		
	Award:	  	2.0% of all cash proceeds (upfront and contingent/earnout) actually paid to investors.
		
	Award Cap:	  	None.
		
	Vesting:	  	Four year vesting, as follows:
		
		  	 25% vests on the first anniversary of grant.

Remaining vests 1/36 per month until fully vested.

		
	Acceleration:	  	Vesting shall accelerate 100% on a Change of Control.

  
 Syndax Pharmaceuticals, Inc., 460 Totten
Pond Road, Suite 650, Waltham, MA 02451 Telephone: 781.419.1400 Fax: 781.419.1420EX-10.20

 Exhibit 10.20 

GENERAL RELEASE AND POST-SEPARATION CONSULTING AGREEMENT 

This General Release and Post-Separation Consulting Agreement (the “Agreement”) is made and entered into by and between
Arlene Morris (the “Executive”) and Syndax Pharmaceuticals, Inc. (the “Company”) (each a “Party,” and together, the “Parties”). 

WHEREAS, Executive and the Company wish to resolve, except as specifically set forth herein, all claims between them arising from or relating
to any act or omission predating the effective date (“Effective Date”) of the General Release and Waiver of Claims (“Release”) attached as Exhibit B to this Agreement; 

WHEREAS, Executive and the Company have decided to terminate their employment relationship; 

WHEREAS, Executive and the Company are parties to an employment agreement, dated March 18, 2012 (the “Employment
Agreement”), and the Company wishes to provide to Executive the termination benefits described in Section 9 of the Employment Agreement (the “Termination Benefits”) in connection with the termination of their
employer-employee relationship; 
 WHEREAS, the Company wishes to provide to Executive additional termination benefits beyond the
Termination Benefits in exchange for Executive’s continued employment through May 14, 2015 and assistance with the transition of Executive’s duties to her successor; 

WHEREAS, the Company wishes to retain Executive as a consultant following the termination of her employment relationship so that Executive may
advise the Company’s executives on matters within Executive’s expertise; 
 NOW THEREFORE, in consideration of the foregoing and
the respective representations, warranties, covenants and agreements set forth in this Agreement, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows: 

1. Confirmation of Termination Benefits under this Agreement. The Company shall pay or provide to Executive all of the Termination
Benefits described in Exhibit A to this Agreement, as, when and on the terms and conditions specified in the Employment Agreement, but as modified by Exhibit A. 

2. Termination of Employment; Consulting Services. 

(a) Executive’s employment with the Company shall terminate effective May 14, 2015 (the “Separation Date”).
Following the Separation Date, and at the request of the Company, Executive will consult with the Company’s executive officers and other employees regarding certain of the Company’s business and activities, as assigned by the Company to
Executive from time to time, through July 13, 2015 (the “Consulting Period”); provided, however, that the parties will mutually agree in writing as to the scope and extent of Executive’s services during the Consulting
Period prior to the Separation Date. Executive acknowledges that the consultation is to be performed from Executive’s home office and/or the Company’s office in Boston, but that the consultation also may require Executive to travel from
time to time. 
 (b) From and after the Separation Date, Executive shall be an independent contractor of the Company, and this Agreement
shall not be construed to create any association, partnership, joint venture, employee or agency relationship between Executive and the Company for any purpose. After the 

 
Separation Date, Executive shall have no authority to bind the Company or its affiliates, and Executive shall not attempt to obligate or bind the Company or any of its affiliates in any way
without the Company’s prior approval. All documents, including but not limited to contracts, agreements, letters of intent, employment agreements and leases, that purport to bind or obligate the Company or any of its affiliates in any respect
must be signed by the appropriate representative(s) of the Company. 
 (c) The Company will provide Executive with support services in its
Boston office for the consulting period following the Separation Date to the extent determined necessary and reasonable by the Company. During the consulting period, Executive may be engaged or employed in any other business, trade, profession or
other activity which does not place Executive in a conflict of interest with the Company; provided, that, during the Consulting Period, Executive shall not be engaged in any business activities involving an HDAC inhibitor being developed to treat
cancer, or otherwise prohibited by the Assignment of Developments Agreement (as defined below and except as provided in Section 8 of this Agreement), between Executive and the Company, without the Company’s prior written consent to be
given or withheld in its sole discretion. 
 (d) The Company shall pay to Executive as full compensation for the consulting services a
monthly consulting fee in the gross amount of Thirty Six Thousand Four Hundred Twenty Five Dollars ($36,425.00) (the “Consulting Fee”) for each month Executive provides consulting services in accordance with Section 2(a).
Executive acknowledges and agrees that the Consulting Fee does not constitute compensation for Executive’s time worked and services rendered through the Separation Date, but rather constitutes consideration for Executive’s agreement to
provide consulting services to the Company on an “as needed” basis and as an independent consultant during the Consulting Period, and that such consideration is above and beyond any wages, salary or other sums to which Executive is
entitled from the Company under the terms of her employment with the Company or under any other contract or law. Executive shall be responsible for costs or expenses incurred by Executive in connection with the performance of the consulting
services, and in no event shall the Company reimburse Executive for any such costs or expenses, except that the Company will reimburse Executive for travel-related expenses when the Company requests that Executive travel in order to provide the
consulting services, and the Company pre-approves any such expenses. 
 (e) With the exception of the Consulting Fee specified
Section 2(d) above, the Company shall withhold the appropriate federal, state and local taxes, as reasonably determined by the Company, from the Termination Benefits paid under this Agreement. Executive acknowledges and agrees that the
Consulting Fee shall be subject to Internal Revenue Service reporting through a Form 1099 issued to Executive. Executive will invoice the Company on a monthly basis for any consulting services provided, and the Company will pay each such invoice
within thirty (30) days of receipt. Payment of the Consulting Fee will be made without any withholdings or deductions by the Company. Executive agrees that she will be exclusively liable for the payment of any taxes which may be assessed
against the Consulting Fee, as well as any additional payments of interest, penalties, or assessment of attorneys’ fees required by a governmental authority, taxing authority, or court in connection with the payment of the Consulting Fee.
Executive further acknowledges that the Company makes no representations or warranties with respect to the tax treatment by any local, state or federal taxing authority of the Consulting Fee or other payments made under this Agreement. 

(f) The Company is and shall be, the sole and exclusive owner of all right, title and interest throughout the world in and to all the results
and proceeds of the consulting services performed under this Agreement (the “Deliverables”), including all patents, copyrights, trademarks, trade secrets and other intellectual property rights (collectively “Intellectual
Property Rights”). Executive agrees that the Deliverables are hereby deemed a “work made for hire” as defined in 17 U.S.C. § 101 for the Company. If, for any reason, any of the Deliverables do not constitute a “work made
for hire,” Executive hereby irrevocably assigns to the Company, in each case without additional consideration, all right, title and interest throughout the world in and to the Deliverables, including all Intellectual Property Rights. 

 (g) The Company may terminate the consulting services provided under this Agreement upon written
notice to Executive only if the Company determines that Executive is not willing, available or able to provide the required consulting services after reasonable attempts by the Company to obtain such consulting services from Executive. In the event
of termination pursuant to this Section 2(g), the Company shall pay to Executive on a proportional basis any Consulting Fees then due and payable for any consulting services completed up to and including the date of such termination. 

3. General Release. 
 (a)
In conjunction with the execution of this Agreement, Executive shall execute the Release, which Release is incorporated into and made a part of this Agreement in full. 

(b) Executive agrees to execute a second bring-down release, in the same form provided in Exhibit B, on the last day of the Consulting Period
(the “Consulting End Date”) which release shall cover the period from the Effective Date through the Consulting End Date. 

4. The Parties agree that their respective rights and obligations under the Employment Agreement shall be superseded by and not survive the
execution of this Agreement, including, but not limited to, Executive’s rights or entitlement to any of the benefits described in Sections 3 (“Annual Bonus”), 5 (“Additional Grant of Stock Options”), 6
(“Strategic Transaction Carve-out”), and 7 (“Promissory Note”) of the Employment Agreement. 
 5.
Executive acknowledges that she has received all compensation to which she is entitled for her work up to her last day of employment with the Company, and that she is not entitled to any further pay or benefit of any kind, for services rendered or
any other reason, other than the Termination Benefits she will receive under this Agreement. 
 6. Effective upon the Separation Date,
Executive shall resign from, and hereby reaffirms her resignation, from all the offices, directorships, and other positions she held with the Company and any of its subsidiaries and affiliates, including without limitation Executive’s board
seat and position and employment as President and Chief Executive Officer of the Company. 
 7. Executive agrees that from and after the
date of the receipt of this Agreement, Executive will not, directly or indirectly, provide to any person or entity any information concerning or relating to the negotiation of this Agreement or its terms and conditions, except: (i) to the
extent specifically required by law or legal process or as authorized in writing by the Company; (ii) to Executive’s tax advisors as may be necessary for the preparation of tax returns or other reports required by law; (iii) to
Executive’s attorneys as may be necessary to secure advice concerning this Agreement; or (iv) to members of Executive’s immediate family. Executive agrees that prior to disclosing such information under parts (ii), (iii), or (iv),
Executive will inform the recipients that they are bound by the limitations of this section. Subsequent disclosure by any such recipients will be deemed to be a disclosure by Executive in breach of this Agreement. 

8. Executive agrees that any sensitive, proprietary, or confidential information or data relating to the Company or any of its affiliates or
other Releasees, as defined in Exhibit B attached hereto, including, without limitation, trade secrets, processes, practices, pricing information, billing histories, customer requirements, customer lists, customer contacts, employee lists, salary
information, personnel matters, financial data, operating results, plans, contractual relationships, projections for new business 

 
opportunities, new or developing business for the Company, technological innovations in any stage of development, the Company’s financial data, long range or short range plans, any
confidential or proprietary information of others licensed to the Company, and all other data and information of a competition-sensitive nature (collectively, “Confidential Information”), and all notes, records, software, drawings,
handbooks, manuals, policies, contracts, memoranda, sales files, or any other documents generated or compiled by any employee of the Company reflecting such Confidential Information, that Executive acquired while an employee of the Company will not
be disclosed or used for Executive’s own purposes or in a manner detrimental to the Company’s interests. In addition, Executive hereby reaffirms Executive’s existing obligations, to the fullest extent permitted by law, under the
Assignment of Developments, Non-Disclosure, Non-Competition, and Non-Solicitation Agreement that Executive entered into with the Company, dated June 28, 2013, or any successor agreement thereto (the “Assignment of Developments
Agreement”, attached hereto as Exhibit C), including, but not limited to, the covenants in the Assignment of Developments Agreement prohibiting Executive from engaging in competition or employee solicitation for six months from the
Separation Date; provided, however, that the non-competition covenant in the Assignment of Developments Agreements shall be modified so that Executive shall only be prohibited, for six months from the Separation Date, from engaging in any activities
in connection with, or working for any company with, an HDAC inhibitor being developed to treat cancer. 
 9. Not later than ten
(10) days after the Separation Date, Executive shall return to the Company all documents (and all copies thereof) and other property belonging to the Company that Executive has in her possession, custody or control. The documents and property
to be returned include, but are not limited to, all files, correspondence, email, memoranda, notes, notebooks, records, plans, forecasts, reports, studies, analyses, compilations of data, proposals, agreements, financial information, research and
development information, marketing information, operational and personnel information, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones and
servers), credit cards, entry cards, identification badges and keys, and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part). Executive
agrees to make a diligent search to locate any such documents, property and information. 
 10. Executive agrees that she will not make to
any person or entity any false, disparaging, or derogatory comments about the Company, its business affairs, its employees, clients, contractors, agents, or any of the other Releasees. The Company agrees not to authorize any communications that
would disparage Executive; provided, however, that the foregoing shall not be violated by truthful statements required by legal process. 

11. This Agreement and the Assignment of Developments Agreement contain the entire understanding and agreement between the Parties relating to
the subject matter of this Agreement, and supersede any and all prior agreements or understandings between the Parties pertaining to the subject matter hereof. This Agreement may not be altered or amended except by an instrument in writing signed by
both Executive and an authorized officer of the Company (other than Executive). Executive has not relied upon any representation or statement outside this Agreement with regard to the subject matter, basis or effect of this Agreement. This Agreement
will be governed by, and construed in accordance with, the laws of the State of Delaware, excluding the choice of law rules thereof. The Parties hereby irrevocably submit to the exclusive jurisdiction of any federal or state court for the county in
which the Company’s principal place of business is located for any dispute arising out of or relating to this Agreement or Executive’s employment with the Company, and each Party hereby irrevocably agrees that all claims in respect of such
dispute or any suit, action or proceeding related thereto may be heard and determined in such courts. The language of all parts of this Agreement will in all cases be construed as a whole, according to the language’s fair meaning, and not
strictly for or against any of the Parties. 

 12. This Agreement will be binding upon and inure to the benefit of the Parties and their
respective representatives, successors and permitted assigns. Neither the waiver by either Party of a breach of or default under any of the provisions of the Agreement, nor the failure of such Party, on one or more occasions, to enforce any of the
provisions of the Agreement or to exercise any right or privilege hereunder will thereafter be construed as a waiver of any subsequent breach or default of a similar nature, or as a waiver of any provisions, rights or privileges hereunder. The
Parties agree to take or cause to be taken such further actions as may be necessary or as may be reasonably requested in order to fully effectuate the purposes, terms, and conditions of this Agreement. This Agreement and the rights and obligations
of the Parties hereunder may not be assigned by Executive without the prior written consent of the Company, but may be assigned by the Company or its successors and assigns without Executive’s permission or consent. If any one or more of the
provisions of this Agreement, or any part thereof, will be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remainder of this Agreement will not in any way be affected or impaired thereby. This Agreement
may be signed in one or more counterparts, each of which will be deemed an original, and all of which together will constitute one instrument. 

13. The Parties agree that nothing contained in this Agreement will constitute or be treated as an admission of liability or wrongdoing by
either of them. In any action to enforce the terms of this Agreement, the prevailing Party will be entitled to recover its costs and expenses, including reasonable attorneys’ fees. 

14. With respect to the Release in Exhibit B of this Agreement, Executive agrees and understands that by signing this Agreement, Executive is
specifically releasing all claims under the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section 621 et seq. Executive acknowledges that she has carefully read and understands this Agreement in its entirety, and executes
it voluntarily and without coercion. 
 (a) Executive is hereby advised to consult with a competent, independent attorney of Executive’s
choice, at Executive’s expense, regarding the legal effect of this Agreement before signing it. Executive shall have twenty-one (21) days from receipt of this Agreement to consider whether to execute it, but Executive may voluntarily
choose to execute this Agreement before the end of the twenty-one (21) day period. The Company will reimburse Executive for her legal fees incurred in connection with the negotiation of this Agreement (up to a maximum of $10,000). 

(b) Executive understands that she has seven (7) days following her execution of this Agreement to revoke it in writing, and that this
Agreement is not effective or enforceable until after this seven (7) day period has expired without revocation. If Executive wishes to revoke this Agreement after signing it, Executive must provide written notice of Executive’s decision to
revoke the Agreement to Robin J. Samuel, Hogan Lovells US LLP, 1999 Avenue of the Stars, Suite 1400, Los Angeles, CA 90071, by no later than 12:01 a.m. on the eighth (8th) calendar day after
the date by which Executive has signed this Agreement (the “Revocation Deadline”). 
 15. The intent of the Parties is that
payments and benefits under this Agreement are either exempt from or comply with Section 409A of the Internal Revenue Code (“Section 409A”) and this Agreement shall be interpreted to that end. The Parties acknowledge and agree
that the interpretation of Section 409A and its application to the terms of this Agreement is uncertain and may be subject to change as additional guidance and interpretations become available. In no event whatsoever shall the Company be liable
for any tax, interest or penalties that may be imposed on Executive by Section 409A or any damages for failing to comply with Section 409A. In such regard, the amount payable under Exhibit A of this Agreement represents an amount that
qualifies for the separate pay exception to Section 409A under Treasury Regulation Section 1.409A-1(b)(9)(iii). 

 16. Executive agrees not to sign this Agreement before her Separation Date. Executive understands
and agrees that this Agreement shall be null and void and have no legal or binding effect whatsoever if: (1) Executive signs but then timely revokes the Agreement before the Revocation Deadline or (2) the Agreement is not signed by
Executive on or before the twenty-first (21st) day after Executive receives it. 
 BY SIGNING BELOW, EXECUTIVE REPRESENTS AND WARRANTS THAT SHE HAS
FULL LEGAL CAPACITY TO ENTER INTO THIS AGREEMENT, HAS CAREFULLY READ THIS AGREEMENT, HAS HAD A FULL OPPORTUNITY TO REVIEW THIS AGREEMENT WITH COUNSEL OF EXECUTIVE’S CHOOSING, AND HAS EXECUTED THIS AGREEMENT VOLUNTARILY, WITHOUT DURESS, COERCION
OR UNDUE INFLUENCE. 
  

			
	 SYNDAX PHARMACEUTICALS, INC.
  

By: /s/ Michael A.
Metzger                                    

Name: Michael A. Metzger
 Title: President & COO

Date: May 13, 2015
	  	 EXECUTIVE
  

/s/ Arlene Morris
 Arlene
Morris
  
 Date: May 12, 2015

 ELECTION TO EXECUTE PRIOR TO EXPIRATION 

OF 21-DAY CONSIDERATION PERIOD 

I, Arlene Morris, understand that I have twenty-one (21) days within which to consider and execute the attached General Release and
Post-Separation Consulting Agreement. However, after having an opportunity to consult counsel, I have freely and voluntarily elected to execute the General Release and Post-Separation Consulting Agreement before such twenty-one (21) day period
has expired. 
  

					
	May 12, 2015	  		  	 /s/ Arlene Morris

	Date	  		  	Arlene Morris

 EXHIBIT A 

SUMMARY OF TERMINATION BENEFITS 
 The
Termination Benefits to be provided under this Agreement, which are all subject to Executive’s full and good faith compliance with this Agreement and the Assignment of Developments Agreement, including the post-employment non-competition
(except as provided in Sections 2(c) and 8 of this Agreement) and non-solicitation provisions in such agreements, consist of: 
  

	A.	The gross amount of Four Hundred Thirty Seven Thousand Ninety Dollars ($437,090.00), which is an amount equal to12 months of Executive’s base salary at the rate in effect at the time of the Separation Date, and
payable in a lump sum on the first regularly-scheduled payroll date occurring on or after the 60th day following the Separation Date, in accordance with this Agreement. 

 

	B.	If Executive elects COBRA continuation coverage, the payment or reimbursement of the healthcare insurance premium for Executive and her covered dependents through the earlier of: (1) 12 months following the
Separation Date; (2) the termination of Executive’s qualification or eligibility for COBRA continuation coverage; or (3) Executive and her dependents becoming eligible for healthcare coverage under another employer’s plan. In
addition, no later than thirty (30) days after the Separation Date, Company will make a one-time payment of $2000 into Executive’s HSA. 

  

	C.	The automatic vesting of all outstanding stock options awards that are held by Executive on the Separation Date. Such amounts are set forth on Schedule A to this Agreement. Executive shall have the right to exercise
such stock options awards until and including January 13, 2017. On January 14, 2017, all stock options awards held by Executive shall expire. 

  

	D.	A transition bonus of up to One Hundred Thousand Dollars ($100,000.00), to be determined and paid in the sole discretion of the Company’s Board of Directors (“Board”) upon Executive’s
successful transition of her duties and responsibilities, which shall include the Company’s successful closing of a private financing in the amount of at least $30,000,000 with Delos Capital within four (4) months from the Separation Date,
and payable in a lump sum on the first regularly-scheduled payroll date occurring on or after the 30th day following the finance closing, in accordance with this Agreement. 

 

	E.	A bonus of Seventy-Five Thousand Dollars ($75,000.00) if the Company successfully completes a firm commitment underwritten public offering of its common stock on Form S-1 filed with the U.S. Securities and Exchange
Commission under the Securities Act of 1933, as amended (“IPO”) on or before December 31, 2015, and payable in a lump sum on the first regularly-scheduled payroll date occurring on or after the IPO, in accordance with this
Agreement. 

 SCHEDULE A 

OPTIONS VESTING SCHEDULE 
  

									
	 Grant Date
	  	Number of Options
Outstanding	 	  	Exercise Price per Share	 
	 5/9/2013
	  	 	40,650	  	  	$	2.46	  
	 5/9/2013
	  	 	204,057	  	  	$	2.46	  
	 5/9/2013
	  	 	40,650	  	  	$	2.46	  
	 9/15/2014
	  	 	19,801	  	  	$	5.05	  
	 9/15/2014
	  	 	48,452	  	  	$	5.05	  
	 12/18/2014
	  	 	32,084	  	  	$	5.08	  

 EXHIBIT B 

GENERAL RELEASE AND WAIVER OF CLAIMS 

Certain capitalized terms used in this Release are defined in the General Release and Post-Separation Consulting Agreement (the “Agreement”)
which I have executed and of which this Release is a part. 
 I hereby confirm my obligations under the Assignment of Developments Agreement (or other
comparable agreement that I have signed, if any). 
 I acknowledge that I have read and understand Section 1542 of the California Civil Code which
reads as follows: 
 A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor
at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” 
 I
hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims provided herein. 

Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers,
directors, agents, servants, employees, shareholders, successors, assigns and affiliates (collectively, the “Releasees”), of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys’ fees,
damages, indemnities and obligations of every kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party
action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this Release, including, but not limited to: all such claims and demands
directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including, but not limited to, claims of intentional and negligent infliction of emotional distress, any and all
tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other
form of compensation; and claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended, the federal Employee Retirement Income Security Act of 1974, as amended,
the federal Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act, as amended, the California Fair Employment and Housing Act, as amended, the New York City Human Rights Law, as amended, the Massachusetts Fair Employment
Practices Law, as amended, the South Carolina Human Affairs Law, as amended, tort law, contract law, wrongful discharge, discrimination, fraud, defamation, emotional distress, and breach of the implied covenant of good faith and fair dealing. 

Nothing in this Release, however, shall be construed in any way to (1) release the Company from its obligation to indemnify me pursuant to the
Company’s indemnification obligation pursuant to written agreement or applicable law; (2) release any claim by me against the Company relating to the validity or enforceability of this release or the Agreement; or (3) prohibit me from
exercising any non-waivable right to file a charge with the United States Equal Employment Opportunity Commission (“EEOC”), the National Labor Relations Board (“NLRB”), or any other government agency (provided,
however, that I shall not be entitled to recover any monetary damages or to obtain non-monetary relief if the agency were to pursue any claims relating to my employment with the Company). 

 I acknowledge that the consideration given under the Agreement for the waiver and release in the preceding
paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing that: (A) my waiver and release do not apply to any rights or claims that may arise on or after
the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; and (C) I have twenty one (21) days from the Separation Date to consider this Release (although I may choose to
voluntarily execute this Release before the expiration of such twenty one day period), and (D) I have seven (7) days from the date I sign this Release to revoke it. 

I hereby represent that I have been paid all compensation owed and for all hours worked, I have received all the leave and leave benefits and protections for
which I am eligible, pursuant to the federal Family and Medical Leave Act, the California Family Rights Act, any Company policy or applicable law, and I have not suffered any on-the-job injury or illness for which I have not already filed a
workers’ compensation claim. 
  

	
	EXECUTIVE:
	
	/s/ Arlene M. Morris
	Signature
	
	Arlene M. Morris
	Printed Name
	
	Date: May 12, 2015

 EXHIBIT C 

ASSIGNMENT OF DEVELOPMENTS AGREEMENT 

 Syndax Pharmaceuticals, Inc. 

ASSIGNMENT OF DEVELOPMENTS, 

NON-DISCLOSURE, NON-COMPETITION, 

AND NON-SOLICITATION AGREEMENT 

RECITALS 
 A. Syndax
Pharmaceuticals, Inc. (the “Company”) is involved in an extremely competitive industry in which confidentiality of its proprietary information is a valuable corporate asset. 

B. The Company’s Confidential Information (defined herein) is vital to the success of the Company’s business and have been or will be
developed or attained by great efforts and expense to the Company. 
 C. I acknowledge that as of the date of this Agreement and continuing
thereafter, I will be provided by the Company with Confidential Information, including trade secrets, concerning the Company and its customers and I recognize the importance of protecting the Company’s rights in and to such Confidential
Information. 
 D. The Company’s competitive position in the line of business in which it is engaged depends in part upon its ability to
safeguard Confidential Information. 
 E. The Confidential Information being provided to me (pursuant to this Agreement) is necessary for the
performance of my duties and could damage the Company or third parties if such Confidential Information were made known to any entity or person engaged in business activities that are in competition with the Company. I acknowledge that without the
Company’s provision of such Confidential Information I would not be able to accomplish my job duties. 
 F. The Company will not
provide, or will not agree to continue to provide, me with this Confidential Information unless I provide the necessary assurances and commitments to protect this information and the Company’s business interests as more fully set forth herein.

 G. This Agreement was made available to me prior to the date hereof so as to provide me with an adequate amount of time in which to read
the entire Agreement and review its provisions with my counsel and advisors. 
 H. I understand the meaning and effect of the terms of this
Agreement, and due to the extremely competitive nature of the business in which Syndax Pharmaceuticals, Inc. is engaged, I agree that the restrictions contained herein are reasonable and necessary. 

NOW, THEREFORE, in consideration of the covenants herein, my employment or continued employment with the Company, and for other good and
valuable consideration, I hereby covenant and agree with the Company as follows: 

 ARTICLE I 

Definitions 
 1.1 Company:
The term “Company” shall mean Syndax Pharmaceuticals, Inc. and any parent, subsidiary, affiliate, successor or assign of Syndax Pharmaceuticals, Inc. for which I work or from which I, as an employee, obtained or could have obtained
Confidential Information and/or benefited from the business relationships involving Syndax Pharmaceuticals, Inc. 
 1.2 Confidential
Information: The term “Confidential Information” shall mean any trade secret, proprietary or confidential information concerning the organization, personnel, business, finances, products, research and development initiatives, preclinical
or clinical trials, or contractual transactions or obligations of the Company, or of any third party which the Company is under an obligation to keep confidential, and that is maintained by the Company as confidential. Such Confidential Information
shall include, but is not limited to, trade secrets, proprietary or confidential information respecting existing and future products and services, designs, methods, formulas, drafts of publications, research, know-how, preclinical or clinical trial
results, techniques, systems, databases, processes, software programs or code, developments or experimental work, works of authorship, customer lists and/or customer information, business plans, marketing plans, financial information, sales
techniques, projects, correspondence with governmental or administrative bodies, the Company’s salary and/or pay rates, other Company personnel information, and all other Company plans and proposals. 

1.3 Developments: The term “Developments” shall mean any invention, modification, discovery, design, development, improvement,
process, software program, work of authorship, documentation, formula, data, technique, know-how, trade secret or intellectual property right whatsoever or any interest therein (whether or not patentable or registrable under copyright, trademark or
similar statutes). 
 ARTICLE II 

Disclosure of Developments 

2.1 I agree that I will forthwith communicate in writing to the Board of Directors of the Company, or such officer or individual as the Board
of Directors of the Company may from time to time designate, a full and complete disclosure of any and all Developments, research and other information, discoveries and improvements made, developed, conceived and/or reduced to practice by me, alone,
or jointly with others (i) while in the employ of the Company and (ii) during a one (1) year period following the termination of my employment or other association with the Company if such Developments, research, discoveries or
improvements relate to the business of the Company. 
 2.2 The business of the Company includes any technical or business interest that has
been worked on by the Company in the past, or in which there is work in progress at the Company during the period of my employment with the Company. The business interests of the Company include Company operations or activities in the planning
stages. I understand that this disclosure of Developments and the following assignment of Developments does not cover any of my patents or patents applications that are filed or based exclusively on inventions made by me before my employment
with the Company. 

  
 2 

 ARTICLE III 

Assignment of Developments 

3.1 If at any time or times during my employment or other association with the Company, I shall (either alone or with others) make, conceive,
create, discover, invent or reduce to practice any Development that (i) relates to the business of the Company or any customer of or supplier to the Company or any of the products or services being developed, manufactured or sold by the Company
or which may be used in relation therewith; or (ii) results from tasks assigned to me by the Company; or (iii) results from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the
Company, then all such Developments and the benefits thereof are and shall immediately become the sole and absolute property of the Company and its assigns, as works made for hire or otherwise. I shall promptly disclose to the Company (or any
persons designated by it) each such Development. I hereby assign all rights (including, but not limited to, rights to inventions, patentable subject matter, copyrights and trademarks) I may have or may acquire in the Developments and all benefits
and/or rights resulting therefrom to the Company and its assigns without further compensation and shall communicate, without cost or delay, and without disclosing to others the same, all available information relating thereto (with all necessary
plans and models) to the Company. 
 3.2 I will assist, upon request, in locating writings and other physical evidence of the making of my
Developments and provide unrecorded information relating to them, and give testimony in any proceeding in which any of my Developments or any application or patent directed thereto may be involved, provided that if I am no longer employed by the
Company, reasonable compensation shall be paid for such services. Notwithstanding the foregoing, no obligation is imposed on the Company to remunerate at a higher rate for the giving of testimony than the rate established by law for the compensation
of witnesses in the court or tribunal where the testimony is taken. To the extent feasible, the Company will use its best efforts to request such assistance at times and places as will least interfere with any other employment of mine. 

3.3 I will promptly disclose to the Company all material which I produce, compose or write, individually or in collaboration with others, which
arises out of work delegated to me by the Company. I agree that all such material constitutes a work for hire, and at the expense of the Company, I will assign to the Company all my interest in such copyrightable material and will sign all papers
and do all other acts necessary to assist the Company to obtain copyrights on such material in any and all countries. 
 3.4 Any Development
relating to the Company’s business made by me within one (1) year following the termination of my employment (and which is required to be disclosed in accordance with Section 2.1 above) shall be presumed to be owned by the Company.

 3.5 I represent that the Developments identified in the Appendix attached hereto, if any, comprise all the Developments that I have made
or conceived prior to my employment by the Company, which Developments are excluded from this Agreement. I understand that it is 

  
 3 

 
only necessary to list the title of such Developments and the purpose thereof, but not details of the Development itself. IF THERE ARE ANY SUCH DEVELOPMENTS TO BE EXCLUDED, THE UNDERSIGNED SHOULD
INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS.                 . 

1. ARTICLE IV 

Non-Disclosure 
 4.1 I
agree that I will not, at any time, whether during or after the termination of my employment, without first obtaining the written approval of the Board of Directors of the Company, or of such officer or individual as the Board of Directors of the
Company may from time to time designate, divulge or disclose to any person or entity outside of the Company, whether by private communications or by public address or publication, or otherwise, any Confidential Information, except to the extent that
such disclosure is necessary to perform my duties and fulfill my responsibilities as an employee of the Company. All original and copies of any Confidential Information or other written materials relating to the business of the Company, however and
whenever produced, shall be the sole property of the Company and shall be surrendered to the Company upon termination of my employment. 

4.2 I shall keep confidential all matters entrusted to me and shall not use or attempt to use any Confidential Information, including
confidential information related to third parties which the Company is obligated to maintain as confidential, except as may be required in the ordinary course of performing my duties as an employee of the Company, nor shall I use any Confidential
Information in any manner which may injure or cause loss or may be calculated to injure or cause loss to the Company, whether directly or indirectly. 

ARTICLE V 

Non-Competition 
 5.1 I
agree that while in the employ of the Company and for six months thereafter (the “Restriction Term”), regardless of the reasons for my termination, I shall not, directly or indirectly, alone or as a consultant, partner, officer, director,
employee, joint venturer, lender or stockholder of any entity (a) accept employment or establish any other relationship with any business within the United States that is in competition with the products or services created, developed or under
development, manufactured or planning to be manufactured, marketed or planning to be marketed, distributed or planning to be distributed, sold or planning to be sold, by the Company at the time of my termination (collectively, the “Products And
Services”), or (b) engage in any business or activity within the United States that is in competition with the Products And Services, provided, however, that the record or beneficial ownership of five (5) percent or less of the
outstanding publicly traded capital stock of any entity shall not be deemed, in and of itself, to be in violation of this Section. Notwithstanding the above, for Company employees classified as sales persons assigned to a distinct geographic area
and for employees classified as service providers with an assigned geographic area, the geographic scope of their Restriction Term shall be limited to the geographic area to which assigned as an employee of Company. 

  
 4 

 ARTICLE VI 

Non-Solicitation Of Employees 

6.1 I agree that during the Restriction Term, regardless of the reasons for my termination, I will not directly or indirectly, alone or as a
consultant, partner, officer, director, employee, joint venturer, lender or stockholder of any entity, recruit or solicit for hire any Company employee, agent, representative or consultant, or any such person who has terminated his/her relationship
with the Company within six months of my departure from the Company. 
 ARTICLE VII 

Company Property 
 7.1 I
agree that during my employment I shall not make, use or permit to be used any Company Property otherwise than for the benefit of the Company. The term “Company Property” shall include all notes, memoranda, reports, lists, records,
drawings, sketches, rolodexes, specifications, software programs, software code, data, computers, cellular telephones, pagers, palm pilots and their equivalents, credit and/or calling cards, keys, access cards, documentation or other materials of
any nature and in any form, whether written, printed, electronic or in digital format or otherwise, relating to any matter within the scope of the business of the Company or concerning any of its dealings or affairs, and any other Company property
in my possession, custody or control. I further agree that I shall not, after the termination of my employment, use or permit others to use any such Company Property. I acknowledge and agree that all Company Property shall be and remain the sole and
exclusive property of the Company. Immediately upon the termination of my employment I shall deliver all Company Property in my possession, and all copies thereof, to the Company. 

ARTICLE VIII 
 Employment
At-Will 
 8.1 I understand that this Agreement does not alter my status as an “at-will” employee of the Company. Accordingly,
I understand that either the Company or I may terminate my employment at any time, for any or no reason, with or without prior notice. 

ARTICLE IX 
 Best Efforts

 9.1 During the period of my employment by the Company, I shall devote my full time and best efforts to the Company’s business,
and I shall neither pursue any business opportunity outside the Company nor take any position with any organization other than the Company without the approval of the Company’s Chief Executive Officer, provided, however, that I may participate
in professional, civic, social and/or charitable activities that do not adversely affect my ability to carry out my responsibilities to the Company. 

  
 5 

 ARTICLE X 

General Provisions 
 10.1 I
agree that this Agreement shall be binding upon me irrespective of the duration of my employment or other association with the Company, the reasons for the cessation of my employment or other association with the Company, or the amount of my wages
and/or salary. 
 10.2 This Agreement sets forth the complete, sole and entire agreement between the parties with respect to the subject
matter herein and supersedes any and all other agreements, negotiations, discussions, proposals, or understandings, whether oral or written, previously entered into, discussed or considered by the parties. No modification or variation to this
Agreement shall be deemed valid unless in writing and signed by the Company. 
 10.3 This Agreement shall be binding upon my heirs,
executors, administrators and legal representatives, and shall inure to the benefit of the successors and assigns of the Company. I shall not assign this Agreement. 

10.4 I represent and warrant to the Company that I am not under any obligations to any person, firm, corporation, or other business entity, and
have no other interest which is inconsistent or in conflict with this Agreement, or which would prevent, limit or impair, in any way, the performance by me of any of the covenants hereunder or my duties in my employment with the Company. I have not
entered into, and shall not enter into, any agreement either oral or written in conflict herewith. 
 10.5 I represent that my employment
with the Company and my performance of all of the terms of this Agreement do not and will not breach any agreement to keep in confidence, proprietary information acquired by me in confidence or trust prior to my employment by the Company, nor will
it violate any non-solicitation and/or non-competition agreements entered into prior to my employment with the Company. I have not entered into, and I shall not enter into, any agreement, either written or oral, in conflict herewith. 

10.6 I agree that any breach of this Agreement by me will cause irreparable damage to the Company and in the event of such breach the Company
shall have, in addition to any and all remedies of law, the right to an injunction, specific performance or other equitable relief to prevent the violations of my obligations hereunder. 

10.7 Any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent
breach of such provision or any other provision hereof. In addition, any amendment to or modification of this Agreement or any waiver of any provision hereof must be in writing and signed by the Company. 

10.8 I agree that each provision and the subparts of each provision herein shall be treated as a separate and independent clause, and the
unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses of the Agreement. Moreover, if one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as
to scope, activity, subject or otherwise, so as to be unenforceable by law, such provision or provisions shall be construed by the appropriate judicial body by limiting or reducing it or them, so as to be enforceable to the maximum extent compatible
with the applicable law as it shall then appear. I hereby further agree that the language of all parts of this agreement shall in all cases be construed as a whole according to its fair meaning and not strictly for or against either of the parties.

  
 6 

 10.9 The headings contained herein are for the sole purpose of convenience of reference, and
shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement. 
 10.10 I
acknowledge and agree that the Company conducts business globally and that the Company has an interest in the uniform interpretation and enforcement of its Employment Agreements. Accordingly, I acknowledge and agree that this Agreement shall be
governed by and construed in accordance with the laws of the Commonwealth of Massachusetts and shall in all respects be interpreted, enforced and governed under the internal and domestic laws of such state, without giving effect to the principles of
conflicts of laws of such state. I further agree that any claims or legal actions by one party against the other arising out of the relationship between the parties contemplated herein (whether or not arising under this Agreement) shall be governed
by the laws of the Commonwealth of Massachusetts and shall be commenced and maintained in any state or federal court located in such state, and I hereby submit to the jurisdiction and venue of any such court. 

  
 7 

 I REPRESENT THAT I HAVE READ THE FOREGOING AGREEMENT, THAT I FULLY UNDERSTAND THE TERMS AND CONDITIONS OF SUCH
AGREEMENT AND THAT I AM KNOWINGLY AND VOLUNTARILY ENTERING INTO THIS AGREEMENT. NO PROMISES OR REPRESENTATIONS (OTHER THAN THE REPRESENTATIONS SET FORTH HEREIN) HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. 

 

							
	Name:	  	Arlene Morris	  		  	
				
	Employee:	  	 /s/ Arlene Morris
	  	        Date: June 28, 2013	  	
		  	Signature	  		  	
				
	Witness:	  	 /s/ John Pallies
	  	        Date: June 28, 2013	  	

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]